MASCC_risk_index v.1

MASCC risk index identifies patients at low risk for poor outcome with febrile neutropenia.

Emma Malm

emma.snygg@hotmail.com

© Cambio CDS

To calculate the total sum for the MASCC risk index.

Use at fever onset (at least 100.4°F/38ºC) to assess risk of complications in febrile neutropenia for patients undergoing chemotherapy treatment. Interpretation: -MASCC ≥ 21 is indicative of a low risk of febrile neutropenia. Consider oral and/or outpatient empirical antibiotic therapy. -MASCC < 21 is indicative of a high risk of febrile neutropenia. Admit for empiric antibiotics if not already inpatient.

Do not use in patients with acute leukemia undergoing induction chemotherapy or allogeneic hematopoietic stem cell transplant conditioning.

Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 Aug;18(16):3038-51. doi: 10.1200/JCO.2000.18.16.3038. PMID: 10944139.

OBSERVATION.mascc.v0, EVALUATION.mascc_assessment.v0